Navigation Links
Vaccine targets tumors where they live

Vaccine strategies are being designed to battle cancer, but their use for metastatic melanoma is a challenge. Effective vaccines against established tumors require tumor-reactive T cells to traffic to the sites of the tumors and are locally activated there in order to kill cancer cells. A problem is that the T cells lose their tumor-killing power once they reach the environment surrounding the tumor. This happens because T cells decrease stimulatory molecules including one called B7.1.

In a study appearing online on June 2 in advance of the print publication of the July 1 print issue of the Journal of Clinical Investigation, Howard Kaufman and colleagues from Columbia University manipulate the local tumor environment as a method for improving systemic anti-tumor immunity. This concept has been suggested in mouse models but had not established in the clinical setting. The data represent the first clinical trial to directly inject a vaccinia virus expressing the B7.1 costimulatory molecule into humans with melanoma.

The researchers show that this vaccine is safe and feasible to use for local delivery into established melanoma lesions. 2 of the injected lesions showed a partial response and 3 were stable. One patient remained alive without disease recurrence for 59 months after vaccination without any other therapy. This approach may be useful for altering the tumor environment in order to induce anti-tumor immunity and provides a foundation upon which other vaccine strategies can be contemplated for local delivery.


'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
8. EuroVacc 02 HIV Vaccine Trial Begins
9. Active Vaccine Prevents Mice From Developing Prion Disease
10. New Vaccine To Be Used For First Time In Polio Outbreak Response
11. Boosting The BCG Vaccine To Beat Tuberculosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2018)... , ... August 23, 2018 , ... ... has for increased sensitivity and specificity over more commonly used analytical techniques. However, ... the added burden of development and validation of methods that must be undertaken ...
(Date:8/26/2018)... ... August 25, 2018 , ... Maire Mayne, an ... energy treated nutraceutical to reduce inflammation and autoimmune disorders and improve overall immune ... well as inflammation. The following data was reported:,     Over ...
(Date:8/23/2018)... ... August 21, 2018 , ... CRISPR-Cas9 gene editing strategies ... species for the robust functional interrogation of complex biological processes. Gene editing in ... immunotherapies, the study of the autoimmunity, the understanding of host-pathogen dynamics that drive ...
Breaking Biology News(10 mins):
(Date:9/12/2018)... ... 2018 , ... Franz Inc. , an early innovator in Artificial Intelligence ... Graphs, and Semantic Web Company , developers of the PoolParty Semantic Suite ... the Noam Chomsky Knowledge Graph. This project is the first aimed at ...
(Date:9/7/2018)... ... 06, 2018 , ... The Discovery on Target (DOT) conference ... industry’s preeminent event on novel drug targets.” BellBrook Labs’ high throughput screening (HTS) ... emerging targets in a quest to find new treatments for disease. , BellBrook ...
(Date:8/31/2018)... , ... August 29, 2018 , ... ... at both the University of Southampton and the Institute of Industrial Science, the ... at sea can dramatically accelerate the exploration and study of hard to reach ...
(Date:8/29/2018)... (PRWEB) , ... August 28, 2018 , ... ... be presenting the results of a safety study performed on an allogeneic (donor ... American Veterinary Regenerative Medicine Association (NAVRMA) conference in September. He is also ...
Breaking Biology Technology: